Proton Beam, Neutron Beam, and Carbon Ion Radiotherapy
Customize your policy alerts
Sign up for Aetna Policy 0270 alerts
Get alerted when Policy 0270 changes without checking for updates manually.
Monitor payer policy activity
This policy defines Aetna's medical necessity, experimental/investigational determinations, and coding guidance for proton beam, neutron beam, and carbon ion radiotherapy for members and providers.
No material clinical or coverage changes in this revision.
Coverage Criteria and Evidence Summary
Proton Beam Therapy - Medical Necessity
Covered when ANY of the following tumor- or patient-specific conditions are met:
From Aetna policy list of medically necessary indications for proton beam radiotherapy (items 1–19).
Proton Beam Therapy - Prostate cancer stance
Check member benefit plan definitions for coverage determination.
Neutron Beam Therapy - Medical Necessity
Covered when ANY of the following are present for salivary gland tumors:
Fast neutron radiotherapy indications for salivary gland malignancies per policy.
Experimental and Investigational
Not covered (experimental/investigational) when any of the following apply:
Policy lists these as experimental/investigational because effectiveness not established.
CIRT experimental status per policy.
ASTRO Group 1 indications (summary)
Professional-society based grouping of indications (ASTRO model policy summaries):
ASTRO model policy (2023) Group 1 general indications.
ASTRO model policy (2017, 2023) Group 1 specifics.
ASTRO Group 2 indications (summary)
ASTRO Group 2 (coverage with evidence development):
ASTRO model policy (2017) Group 2 indications for CED.
HTA consensus and evidence limitations
General evidence-based stance from multiple HTAs and assessments:
Summarizes findings from VHA, CADTH, AHRQ, VATAP, KCE and others.
Noted across multiple HTAs and assessments.
Concerns reported by multiple assessments (KCE, VATAP, CADTH, etc.).
Supported, Unsupported, and Trial/Registry Use
Indications and contexts where particle therapy is discussed as appropriate or insufficiently supported:
Supported by MSAC, Cancer Care Alberta, NHS and other assessments.
Noted by multiple HTAs and guideline bodies as low-quality or insufficient evidence.
Multiple systematic reviews and assessments emphasize the need for RCTs and registries.
Cited across assessments for dosimetric and long-term-risk rationale.
Evidence-based considerations (informational)
Evidence- and guideline-derived considerations relevant to coverage determinations
NCCN and other guidance note consideration when photon constraints cannot be met; HTAs emphasize limited comparative evidence.
Based on Romesser et al., McDonald et al. series.
Reports by Amsbaugh et al. and Greenberger et al.
Several small series summarized in policy.
Includes Efstathiou et al., Clivio et al. planning studies.
Evidence summaries by indication
Summary findings and caveats from cited studies (evidence-based observations):
Small patient series; NCCN does not list PBT for uterine neoplasms.
Limited sample sizes and adjunct therapies confound interpretation.
NCCN pancreatic guideline does not mention PBT.
NCCN rectal cancer guideline does not list PBT.
Small cohorts; further randomized investigation recommended.
Dose variations studied; further study needed.
NCCN states PBT may be considered in certain circumstances for thymic tumors.
Pediatric CNS dosimetric rationale cited.
Additional prospective data required.
Limited sample sizes and retrospective designs.
Recommended evaluation indications
Situations discussed where particle therapy is recommended or should be evaluated
Policy and reviews recommend evaluation of protons for these scenarios while avoiding treatment delay.
Evidence context
Evidence summaries supporting use
Findings require validation in prospective comparative trials.
Pediatric CNS tumors
Pediatric CNS considerations
Benefit is inferred from dosimetry and cohort analyses; randomized long-term data lacking.
Reported clinical indications and outcome summaries
Reported clinical contexts with reported outcomes (not formal coverage criteria):
Single-institution and registry data summarized.
Evidence from multi-institutional single-arm trials and feasibility studies.
Hoppe et al. registry data summarized.
Background evidence summaries (informational)
Evidence-summary statements relevant to coverage determinations
Editorials and registry data emphasize dosimetric advantage but limited clinical confirmation.
Lin et al. randomized trial findings summarized.
Guideline and HTA statements characterize proton therapy for prostate as promising but not proven.
Systematic reviews report heterogeneous outcomes and limited quality.
Further randomized study recommended.
Evidence-based coverage groupings
Coverage stance and evidence highlights from the document:
Based on randomized trial (Laramore et al.) and subsequent series.
Evidence considered limited but supportive in selected indications.
Ludwig Boltzmann and other systematic reviews concluded insufficient evidence for superiority.
HTAs and guideline bodies emphasize limited generalizability and need for RCTs.
Coverage rationale and evidence-based conclusions
Evidence summary and resulting policy stance
Systematic reviews identified limited comparative data and geographic concentration of studies.
Meta-analysis included 12 studies and 897 patients; limitations include case-series designs and regional concentration of reports.
The policy lists example adult ICD‑10 diagnoses for which proton beam radiotherapy (PBRT) is identified as not-covered (examples, not all‑inclusive). These include malignancies of the small intestine (C17.0–C17.9), rectum/rectosigmoid/anus (C19–C21.8), liver and intrahepatic bile ducts (C22.2–C22.9), pancreas (C25.0–C25.9), lung including non‑small‑cell lung carcinoma (C34.00–C34.92), ethmoidal sinus (C31.1), malignant melanoma of skin (C43.0–C43.9), mesothelioma (C45.0–C45.9), and a range of soft tissue and other adult tumor codes listed in the ICD‑10 tables in the policy.
Multiple health‑technology assessments and reviews conclude it is not appropriate to routinely propose proton therapy for certain indications because of inadequate or low‑quality evidence. Assessments specifically note proton therapy is presently not recommended or considered premature for indications including non‑small‑cell lung cancer and some thoracic cancers, hepatocellular carcinoma, prostate cancer, esophageal cancer, breast cancer, and routine re‑irradiation outside prospective studies or registries.
Available assessments and guideline statements do not support routine primary use of proton beam therapy for localized prostate cancer outside clinical trials or registries. Comparative evidence indicates outcomes with PBRT and IMRT are similar, randomized data have not demonstrated superiority, and technology assessments have judged the comparative effectiveness and value as insufficient to justify routine proton use for prostate cancer absent plan‑specific coverage provisions.
Multiple guideline sections and technology assessments do not recommend routine proton therapy for several malignancies, including Hodgkin lymphoma and cholangiocarcinoma. For lymphoma, guideline panels and technology reviews report insufficient clinical outcome data to demonstrate PBT superiority and do not make broad recommendations for routine use. International and national reviews likewise do not endorse routine PBT for cholangiocarcinoma, and NCCN guidance does not list PBT as a standard option for several of these sites.
For multiple tumor types — for example uterine neoplasms, pancreatic adenocarcinoma, and rectal cancer — cited NCCN guidance and systematic reviews do not list proton beam therapy as a standard therapeutic option. The document summarizes small feasibility and retrospective series for some of these sites but concludes that clinical outcome evidence is limited and that NCCN does not include PBT as a recommended standard treatment for these indications.
The policy states that the use of protons is not justified if it would cause a delay or lead to inferior oncologic care compared with available photon‑based treatments. Treatment decisions should avoid unacceptable delays (for example delaying adjuvant radiotherapy) or selection of PBT when equivalent photon techniques can deliver appropriate oncologic therapy without compromise.
For CNS malignancies other than skull‑base and cervical spine chordomas and chondrosarcomas, ASTRO and several assessments indicate the potential benefit of proton beam therapy remains theoretical and requires further study. While protons are commonly evaluated for selected skull‑base lesions, evidence for broader CNS indications is limited and international guidelines generally make no broad recommendation for routine PBT use outside select skull‑base or pediatric indications.
NCCN guidance does not preferentially recommend proton therapy over photons for B‑cell lymphomas and advises that for esophageal cancer proton therapy data are early and evolving; NCCN states that PBT for esophageal cancer should ideally be delivered in the context of a clinical trial. Overall, NCCN does not list PBT as the default modality for most lymphoma or esophageal scenarios.
Carbon ion radiotherapy (CIRT) is considered experimental or unproven for the oncologic indications assessed in the policy. Systematic assessments identified multiple studies but concluded that for the majority of evaluated indications there is insufficient evidence to establish superiority or equivalence versus standard irradiation; therefore CIRT is excluded from routine coverage absent strong investigational justification or case‑level review.
Across assessed oncologic indications, carbon ion radiotherapy lacks sufficient high‑quality evidence to conclude superiority or inferiority compared with standard photon or proton irradiation. The systematic reviews and meta‑analyses summarized in the policy report promising outcomes in some series (for example unresectable bone sarcomas) but emphasize geographic concentration of studies, heterogeneity, and lack of randomized comparative data; thus CIRT remains experimental for the listed indications.
The document’s references section includes citations specific to Neutron Beam Therapy, but this references listing does not itself state coverage exclusions; substantive policy statements about neutron therapy indications and evidence appear elsewhere in the policy text and summaries.
This Clinical Policy Bulletin provides a general summary of plan benefits and evidence considerations and is not a contract nor a substitute for the member’s benefit plan documents. Providers and members should refer to the member’s plan provisions for definitive coverage and contractual terms.
The policy explicitly states that proton beam radiotherapy is considered experimental and investigational for all indications not specified as medically necessary in the bulletin; example adult lists are provided in the policy text to illustrate conditions for which PBRT would not be considered medically necessary.
The Washington State Health Technology Clinical Committee determined that proton beam therapy is covered for specified primary cancers in adults (e.g., esophageal, head/neck, skull‑based, hepatocellular carcinoma, brain/spinal, ocular) subject to conditions, and that PBT is not covered for other adult conditions beyond those specified, reflecting regional coverage restrictions noted in the assessments.
For non‑small‑cell lung cancer and several other indications, technology assessments and guideline reviews conclude evidence is insufficient to support routine PBT use; comparative effectiveness versus established photon options (including SBRT for early‑stage NSCLC) is uncertain and PBT does not meet routine‑use criteria outside trials or registries.
Where guidelines or health‑technology assessments explicitly state evidence is insufficient (for example ASTRO reviews, AHRQ assessments, and other HTAs), the policy summarizes that proton beam therapy would generally be considered not medically necessary relative to established photon therapies unless specific, justifying clinical circumstances exist or the patient is enrolled in a prospective trial/registry.
Many feasibility and dosimetric optimization studies cited in the policy are small and primarily report planning or technical outcomes rather than clinical effectiveness. The policy highlights that where only feasibility or dosimetric data exist without comparative clinical outcome evidence, PBRT should be considered unproven for those indications pending higher‑quality clinical data.
The policy cautions against using protons solely when advanced photon techniques (e.g., IMRT/VMAT, brachytherapy) can provide equivalent oncologic care, particularly if proton access would delay treatment or compromise outcomes. Where photon constraints can be met, photon‑first approaches are recommended and proton selection should be justified by inability of photon techniques to meet normal‑tissue constraints.
Comparative evidence for many CNS indications is limited and of poor quality; the policy notes absence of demonstrated superiority of PBT for broad CNS tumor groups and cites some adjusted analyses suggesting worse outcomes in particular series, underscoring the need for caution and additional justification when proposing PBT for non‑skull‑base CNS tumors.
For localized prostate cancer, the policy reflects that evidence is insufficient to show a clinical benefit of proton therapy over established options such as IMRT. Randomized data have not demonstrated superiority, and comparative clinical‑effectiveness assessments rate the evidence as inadequate to support routine proton use for most prostate indications.
CIRT is deemed to lack sufficient evidence of superiority or well‑established indications and therefore is considered experimental. The policy states that carbon‑ion therapy should be excluded from routine coverage and that investigational justification or case‑level review would be required for its consideration.
Systematic assessments summarized in the policy found that for many oncologic indications (54 assessed sites) neither superiority nor inferiority of CIRT versus standard irradiation can be concluded from current evidence; accordingly, carbon ion radiotherapy must currently be treated as experimental and not medically necessary for routine coverage.
The policy includes an extensive references list for carbon ion radiotherapy; these citations are provided for context and do not themselves change the policy’s conclusion that CIRT is experimental and not established for routine coverage.
Billing Codes and Diagnostic Mapping
| 77520 | Proton treatment delivery; simple, without compensation. |
| 77522 | Proton treatment delivery; simple, with compensation. |
| 77523 | Proton treatment delivery; intermediate. |
| 77525 | Proton treatment delivery; complex. |
| 61796 | Stereotactic radiosurgery (particle beam, gamma ray or linear accelerator); 1 simple cranial lesion. |
| 61797 | Each additional cranial lesion, simple. |
| 61798 | 1 complex cranial lesion. |
| 61799 | Each additional cranial lesion, complex. |
| 63620 | Stereotactic radiosurgery (particle beam, gamma ray, or linear accelerator); 1 spinal lesion. |
| 63621 | Each additional spinal lesion, complex. |
| No codes listed |
| C00.0-C00.9 | Malignant neoplasm of lip |
| C11.0-C11.9 | Malignant neoplasm of nasopharynx |
| C22.0 | Liver cell carcinoma |
| C69.30-C69.32 | Malignant neoplasm of choroid |
| C71.0-C71.9 | Malignant neoplasm of brain |
| C48.0 | Malignant neoplasm of retroperitoneum (retroperitoneal sarcoma) |
| Q85.01 | Neurofibromatosis, type 1 |
| Z15.01 | Genetic susceptibility to malignant neoplasm of breast |
| Z94.0 | Kidney transplant status |
| C34.00-C34.92 | Malignant neoplasm of bronchus and lung [including non-small-cell lung carcinoma] |
| C50.01-C50.929 | Malignant neoplasm of breast |
| C61 | Malignant neoplasm of prostate |
| C25.0-C25.9 | Malignant neoplasm of pancreas |
| C43.0-C43.9 | Malignant melanoma of skin |
| none listed | No CPT/HCPCS/ICD codes are specified in this excerpt. |
Prior Authorization, Documentation, and Decision Support
Prior Authorization — Verify Plan-Specific Requirements
Prior authorization requirements for particle-beam therapies vary by indication, plan, and complexity of the proposed treatment. Providers should verify prior authorization requirements with the member's benefit plan before scheduling PBRT, NBT, or CIRT. When prior authorization is required, documentation should demonstrate that indication-specific and plan-level medical necessity criteria are met.
- Verify plan-specific prior authorization requirements and medical necessity definitions before submission.
- When prior authorization is requested, include indication-specific documentation (tumor type, stage, prior therapies, intent of treatment).
- For ICD-10 diagnoses listed as not covered in this policy for adults, expect denial risk if PBRT is requested for those indications.
Indication-Based Prior Authorization
Indication-based prior authorization is recommended. Coverage determinations commonly reference indication groupings (e.g., ASTRO Group 1 vs Group 2). Prior authorization submissions should identify the indication, cite relevant guideline grouping (if applicable), and provide supporting clinical evidence.
- Document whether the indication aligns with Group 1 (frequently supported) or Group 2 (coverage with evidence development) per ASTRO model policies where applicable.
- For Group 2 indications, include rationale for coverage with evidence development or trial/registry enrollment plans.
Prior Authorization for Limited / Selected Indications
Prior authorization is recommended for selected or limited indications where guidelines and health-technology assessments recommend PBRT only for specific diagnoses or after multidisciplinary review. Submissions should include multidisciplinary tumor board review notes when applicable.
- Include tumor board documentation when PBRT is proposed for adult indications that some assessments consider conditional or restricted.
- For adult indications noted as covered with conditions by regional assessments (e.g., Washington State), include documentation that conditions are met.
Prior Authorization Recommended for PBT
Prior authorization is recommended when proton-beam therapy (PBT) is proposed, particularly for indications lacking clear guideline endorsement or high-quality comparative evidence.
- For adult indications deemed experimental/investigational in this policy, anticipate case-level review and potential denial.
- For pediatric and other supported indications, prior authorization supports timely coordination of care and documentation of intent.
Prior Authorization Recommended for Complex PBRT Cases
Complex PBRT cases (e.g., multiple isocenters, many energy layers, combined modality treatment, reirradiation) should undergo prior authorization with submission of detailed treatment planning and intent documentation.
- Provide a summary of the proposed treatment plan, number of isocenters, beam arrangement, and expected energy layers.
- Include robustness analysis, image-guided setup plans, and how organ motion will be managed.
- Document treatment intent (curative vs palliative), prior radiation history, and timing since prior RT if reirradiation is proposed.
Prior Authorization — Avoid Treatment Delay
Prior authorization processes must avoid causing unacceptable delays in oncologic care. Submissions should include timing constraints to ensure adjuvant or time-sensitive radiotherapy starts within clinically acceptable windows.
- Document planned radiotherapy start date and any postoperative timing limits (e.g., adjuvant RT initiation goals).
- Prior authorization reviews should be expedited for cases where delay could harm outcomes.
Prior Authorization / Registry Enrollment Recommended
When proton therapy is used as consolidative therapy (e.g., Hodgkin lymphoma) or for indications with limited evidence, prior authorization or registry/IRB-approved protocol enrollment is recommended to support evidence development and tracking of outcomes.
- Include registry or IRB protocol identifiers when available.
- If not enrolled in a trial, provide rationale for use outside of research and evidence of multidisciplinary review.
Consideration for Trial Enrollment
When data are limited or evolving, consider enrollment of patients in prospective clinical trials. Guidelines (e.g., NCCN for esophageal cancer) recommend ideally treating with PBT within a clinical trial when feasible.
- Document trial eligibility or reasons trial enrollment was not possible.
- Provide trial or registry identifiers and informed consent documentation when applicable.
Carbon Ion Therapy Experimental — Case Review Suggested
Carbon ion radiotherapy (CIRT) is considered experimental/unproven for the indications assessed. Case-level review and institutional IRB/trial enrollment are suggested prior to authorization for CIRT.
- CIRT should be documented as investigational in the submission; include protocol and justification.
- Expect case-by-case review and likely denial outside of approved clinical trials or registries.
Prior Authorization Not Addressed in This Segment
Some parts of this policy and its reference listings do not specify prior authorization rules. Where the policy or references are silent, revert to the member's benefit plan provisions and Clinical Policy Bulletin for authorization processes.
- No specific prior authorization requirements are contained in certain reference sections; check plan documents.
- If prior authorization is not addressed in the policy excerpt, use standard plan submission pathways.
Prior Authorization Not Specified in These Chunks
Some reference chunks and coding lists do not specify prior authorization or denial requirements. Providers should not assume coverage based solely on code listings; verify clinical criteria and plan rules.
- Coding lists alone do not guarantee coverage; clinical criteria and plan provisions drive authorization decisions.
- Contact the payer for any code- or indication-specific prior authorization instructions.
Denial Risk for Non-Covered ICD-10 Indications
Denial risk is elevated when PBRT is requested for ICD-10 diagnoses specifically listed as not covered for adults in this policy. Providers should confirm the ICD-10 code maps to a covered indication and include supporting documentation.
- Review the policy's 'ICD-10 codes not covered' lists before submission.
- If the diagnosis is on the not-covered list, include compelling justification and tumor-board documentation if requesting exception review.
Coverage Restrictions for Adults per Washington State Assessment
Regional technology assessments (e.g., Washington State) place coverage restrictions for adults for many indications. Prior authorization submissions should reference such assessments and demonstrate compliance with their conditions when relevant.
- For adults, include documentation that meets regional assessment conditions (e.g., specific cancer types, multidisciplinary review) when applicable.
- If the regional assessment does not support coverage for the indication, be prepared for denial.
Unproven Comparative Effectiveness May Lead to Denial
In the absence of high-quality randomized comparative evidence or guideline endorsement, PBRT requests for many indications may be denied or require enrollment in evidence-development programs.
- Include the best available comparative evidence and rationale for expected benefit over alternative therapies.
- If comparative effectiveness is unproven, document why alternatives are unsuitable or would exceed normal tissue constraints.
Evidence Insufficiency May Prompt Denial
Insufficient evidence for an indication is a common reason for denial. Providers should supply prospective trial data, registry enrollment, or robust rationale when evidence is limited.
- When evidence is insufficient, document the clinical need, prior treatments tried, and why standard options are unsuitable.
- Consider suggesting treatment within a clinical trial or registry if available.
Guideline Non-Endorsement May Affect Coverage
Lack of guideline endorsement for an indication (e.g., NCCN, ASTRO) may affect coverage decisions. Prior authorization should reference current guideline positions and explain deviation when proposing PBRT.
- Cite specific guideline statements and provide clinical justification when requesting PBRT outside guideline-listed options.
- If guidelines recommend photon-first approaches, document attempts or infeasibility of photon-based therapy.
Timeliness of Therapy — Expedite When Clinically Needed
Timeliness of therapy is critical. Prior authorization processes must not create delays that compromise oncologic outcomes (for example, undue delay of adjuvant radiotherapy). Document time-sensitive treatment milestones in the authorization request.
- Provide planned treatment initiation dates and clinical rationale for timing.
- Requests for expedited review should state the clinical consequences of delay.
Technical Planning / Setup Risks — Document Mitigation
Technical planning and setup risks (e.g., sensitivity to tissue density, organ motion, end-of-range uncertainty) should be addressed in submissions. Include treatment-planning reports, robustness analyses, and daily image-guidance strategies.
- Attach planning CT/MRI summaries, motion-management strategies, and verification QA documentation.
- For mediastinal and thoracic plans, document respiratory gating, margins, and verification steps to mitigate dose uncertainty.
Higher Risk of Damage to Surrounding Tissues — Justify Use
Certain technologies (e.g., neutron beams) carry higher risks to surrounding tissues due to greater energy deposition; when used, prior authorization should include detailed risk-benefit analysis and justification.
- Explain why neutron beam therapy is preferred for the specific tumor type and why alternatives are unsuitable.
- Provide toxicity mitigation strategies and expected benefit over standard approaches.
Plan-Level Medical Necessity Considerations
Benefit-plan medical necessity considerations may include comparative costs of alternative treatments. Prior authorization should reference plan definitions of medical necessity where cost-comparative considerations apply.
- Check member benefit plan language for medical necessity definitions and comparative cost considerations.
- Include discussion of why alternative, lower-cost options are not appropriate when relevant.
This Section Contains Only Literature References — Check Plan Rules
This portion of the policy includes literature references; some sections contain only references and do not specify authorization, denial, or documentation requirements. Providers should not infer coverage from referenced studies alone.
- When the policy section is reference-only, follow the Clinical Policy Bulletin and plan provisions for submission requirements.
- Provide clinical documentation as required by the plan even if literature supports the intervention.
Documentation Requirements for Authorization and Case Review
Documentation expectations for prior authorization and case review: provide comprehensive, indication-specific clinical records and treatment-planning information to support medical necessity determinations.
- Documentation of indication-specific criteria: tumor histology, stage, size, resection status, and rationale for PBRT versus alternatives.
- Indication categorization: state whether the case aligns with ASTRO Group 1 or Group 2 and provide supporting evidence.
- Supportive clinical trial documentation: include protocol details, eligibility, dosing, and follow-up plans when applicable.
- Suggested documentation elements: prior radiation history, time since prior RT, performance status (e.g., Karnofsky), imaging, and pathology reports.
- Treatment planning and QA documentation: dose distributions, DVHs, robustness analysis, image-guided setup, and daily verification plans.
- Required clinical documentation: tumor histology/grade, proximity to critical structures, prior therapies, intent of treatment (curative vs palliative).
- Trial eligibility-like documentation: when using trial criteria, include Child-Pugh status, lesion number/size limits, and performance status where relevant.
- Planning and justification notes: explain management of internal organ motion, immobilization, and plan robustness for mediastinal and thoracic cases.
Evidence-Driven Sequencing — Photon-First When Feasible
Evidence-driven sequencing and conservative use of PBRT are expected. Where normal tissue constraints can be met with photon-based therapy, photon-first approaches (IMRT/VMAT/SRS) should be considered and documented before PBRT is pursued in many adult settings.
- When photon therapy can meet constraints, document why PBRT is preferred or why photon approaches are not feasible.
- Document prior use or consideration of standard therapies when policy or guidelines recommend photon-first approaches.
Comparative Approach Requirement — Document Alternatives Considered
Comparative approach requirement: document consideration of advanced photon techniques (IMRT/VMAT/SRS) and why particle therapy is expected to provide clinically meaningful advantage for the individual patient.
- Provide comparative dosimetry summaries and expected normal tissue sparing with PBRT versus advanced photon plans.
- If proton therapy follows surgery (pre- or post-operative) or is combined with other modalities, document the multidisciplinary treatment plan.
Stepwise Use After Standard Therapies
Stepwise use after standard therapies: For select indications (e.g., conjunctival SCC/OSSN), standard first-line therapies (surgery, topical agents) are expected before considering PBRT; document prior treatments and indications for PBRT.
- For indications where standard therapies exist, include records of prior attempts and reasons for failure or ineligibility.
- When PBRT is used as salvage or for refractory disease, attach prior-treatment summaries and timelines.
Prostate Therapy Sequencing and Evidence Considerations
Prostate therapy sequencing: randomized trials comparing proton therapy to IMRT are ongoing; until high-quality evidence is available, proton therapy for localized prostate cancer is considered clinically equivalent to IMRT and medical necessity is determined by the member's benefit plan.
- Check benefit plan descriptions for coverage position on prostate PBRT.
- If requesting PBRT post-prostatectomy or in the postoperative setting, include comparative rationale and expected benefits.
Use of Proton-Beam Therapy Often Described in Combination With Other Modalities
Use of proton-beam therapy is often described in combination with surgery, IMRT, and intra-operative electron radiotherapy (IOERT). Multidisciplinary coordination and documentation of combined-modality intent are expected in authorization submissions.
- Include surgical reports, planned sequence of therapies, and rationale for combining modalities.
- Document expected contribution of PBRT to the overall treatment strategy and goals (local control, organ preservation, reduced toxicity).
Provider Action — Refer to Clinical Policy Bulletin and Plan Provisions
Providers should refer to the Clinical Policy Bulletin and the member's plan provisions for the definitive guidance on prior authorization processes, documentation formats, and coverage determinations.
- Clinical Policy Bulletins assist in administering plan benefits but do not replace plan-specific benefit language.
- When in doubt, contact the payer's medical policy/prior authorization help line for submission instructions and required forms.
Background and Scope
Background: Proton beam radiotherapy (PBRT) is an external‑beam charged‑particle modality that delivers dose with a distinct depth‑dose distribution (Bragg peak) enabling reduced exit dose and potential sparing of adjacent normal tissues. PBRT is most commonly considered for tumors adjacent to critical structures, many pediatric malignancies, selected skull‑base or ocular tumors, and some re‑irradiation scenarios where photon techniques cannot meet normal‑tissue constraints.
Definitions and Key Terms
Policy Dates and References
Policy became effective on 1998-07-16.
Policy last reviewed on 2023-10-03.
Next scheduled policy review on 2024-03-14.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.